RUTHERFORD, N.J., January 20, 2014 (GlobeNewswire) –Â Cancer Genetics, Inc.,Â (Nasdaq: CGIX) (â€œCGIâ€ or â€œthe companyâ€), an emerging leader in DNA-based cancer diagnostics, announced today the launch of their ExpandDxTMÂ collaborativeÂ testing program. CGIâ€™s ExpandDx program, which utilizes VENTANA digital pathology technology from Roche, allows community-based hospitals and pathology labs to partner with CGI through remote consultations, and enables access to a broader range of tests that expand the clinical testing capabilities of community labs and hospitals. The technical-only testing service provides community hospitals and pathology labs with the most advanced testing technologies available, and facilitates increased collaboration on both atypical and difficult cancer cases.
â€œWe are very excited to partner with Cancer Genetics to provide comprehensive digital pathology solutions through their ExpandDx testing program,â€ said Rod Cotton, Senior Vice President at Roche Diagnostics Corporation.Â â€œThis new service is an example of their innovation and leadership in the field of cancer diagnostics. It will enable a more collaborative and responsive diagnosis process for community-based pathologists and help them fulfill their mission to empower personalized cancer treatment.â€
Through CGIâ€™s ExpandDxÂ collaborative testing program, the technical component will be performed at CGI laboratories, and clinicians will have the option of interpreting and signing out their patientsâ€™ test results. By allowing clinicians to sign out cases remotely and share cases with other team members, the program enables smaller labs to manage resources while still leveraging CGIâ€™s unique tests and expertise in oncology diagnostics.
â€œAs care centers and clinicians look for ways to improve cost efficiency, technical-only testing offers opportunity for providers to more actively collaborate in the diagnosis process and manage costs for patients,â€ said Lan Wang, M.D., Medical Director at Cancer Genetics.Â â€œCGIâ€™s ExpandDx technical-only testing will ensure that community-based hospitals and pathology labs have access to the same cutting-edge oncology testing available at larger centers, and will allow the clinical community to collaborate on difficult cases.â€
About Cancer Genetics
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital andÂ HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
Cancer Genetics, Inc.
LifeSci Advisors, LLC
Source: Cancer Genetics, Inc.